Application of PPAR agonists, one of the anti-hyperglycaemic drug classes, has been proven to be effective in ameliorating NAFLD, as well as hyperlipidemia [47]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.